Rapid Dose Therapeutics Corp.
DOSE.CNCNQHealthcare● Active
$0.09
$-0.01(-5.26%)
Market Cap$11869830
P/E Ratio—
52W High$0.24
52W Low$0.085
Rapid Dose Therapeutics Corp. (DOSE.CN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DOSE.CN · earnings · updated Jun 10, 2026
Latest Earnings
Q1 FY2026Report Date: Jan 27, 2026EPS Actual
-$0.01
Revenue
$0.00B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Jan 27, 2026
After Market Close
DOSE.CN reports quarterly as a CNQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Next earnings date not yet announced.
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2026 | Jan 27, 2026 | — | -$0.01 | — | $0.00B | — | — |
| — Q4 FY2025 | Oct 28, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q2 FY2025 | Jun 30, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2025 | Jan 29, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2025 | Jan 27, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 28, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2024 | Jul 26, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q1 FY2024 | Jan 29, 2024 | — | -$0.02 | — | $0.00B | — | — |
Q1 FY2026
Jan 27, 2026
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Oct 28, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2025
Jun 30, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Jan 29, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2025
Jan 27, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 28, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Jul 26, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2024
Jan 29, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for DOSE.CN.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Jan 27, 2026 | — | $0.14 | $0.14 | +0.00% |
| — Q4 FY2025 | Oct 28, 2025 | — | $0.16 | $0.16 | +0.00% |
| — Q2 FY2025 | Jun 30, 2025 | — | $0.21 | $0.19 | -11.90% |
| — Q1 FY2025 | Jan 29, 2025 | — | $0.21 | $0.21 | +0.00% |
| — Q1 FY2025 | Jan 27, 2025 | — | $0.20 | $0.21 | +2.50% |
| — Q3 FY2024 | Aug 28, 2024 | — | $0.14 | $0.15 | +11.11% |
| — Q3 FY2024 | Jul 26, 2024 | — | $0.18 | $0.18 | +0.00% |
| — Q1 FY2024 | Jan 29, 2024 | — | $0.16 | $0.16 | +0.00% |
Q1 FY2026+0.00%
Report Date
Jan 27, 2026
EPS Beat/Miss
—
Price Before
$0.14
Price After
$0.14
Q4 FY2025+0.00%
Report Date
Oct 28, 2025
EPS Beat/Miss
—
Price Before
$0.16
Price After
$0.16
Q2 FY2025-11.90%
Report Date
Jun 30, 2025
EPS Beat/Miss
—
Price Before
$0.21
Price After
$0.19
Q1 FY2025+0.00%
Report Date
Jan 29, 2025
EPS Beat/Miss
—
Price Before
$0.21
Price After
$0.21
Q1 FY2025+2.50%
Report Date
Jan 27, 2025
EPS Beat/Miss
—
Price Before
$0.20
Price After
$0.21
Q3 FY2024+11.11%
Report Date
Aug 28, 2024
EPS Beat/Miss
—
Price Before
$0.14
Price After
$0.15
Q3 FY2024+0.00%
Report Date
Jul 26, 2024
EPS Beat/Miss
—
Price Before
$0.18
Price After
$0.18
Q1 FY2024+0.00%
Report Date
Jan 29, 2024
EPS Beat/Miss
—
Price Before
$0.16
Price After
$0.16
Beat Rate0 / 8 quarters
Largest Move-11.90% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DOSE.CN ends December
Rapid Dose Therapeutics Corp. (DOSE.CN) most recently reported earnings on January 27, 2026 for Q1 FY2026, posting EPS of $-0.01 (in line with the analyst consensus of —).
Each quarter, investors track DOSE.CN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DOSE.CN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DOSE.CN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DOSE.CN earnings · 4 questionsRapid Dose Therapeutics Corp.'s next earnings report is expected around TBD. DOSE.CN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DOSE.CN historically reports after market close (AMC).
DOSE.CN earnings datewhen is DOSE.CN earningsDOSE.CN next earnings datewhen does DOSE.CN report earningsDOSE.CN earnings calendar
▸ Source: FMP · Rapid Dose Therapeutics Corp. SEC filings · US GAAP · Rapid Dose Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026